Navigation Links
Vasogen Announces Third Quarter 2007 Results
Date:10/9/2007

roceeding as planned and we remain on track with our objective of

launching Celacade in Europe before the end of the year.

- Today we announced that a recently published book,

"Immune Dysfunction and Immunotherapy in Heart Disease," discusses

the Celacade System for the treatment of heart failure. The chapter

entitled "Anti-inflammatory therapy in heart failure," describes how

the growing understanding of the role inflammation in heart failure

has led to new treatment modalities and describes the potential of

Celacade to target this underlying pathology. The authors of the

chapter describe the mechanism of action of Celacade and review the

results of the ACCLAIM trial. Regarding the results of the trial, the

authors state: "These findings are consistent with the role that

chronic inflammation plays in the development and progression of HF

and are particularly impressive in the large subgroup of

NYHA Class III or IV patients who had not experienced a prior heart

attack and in all NYHA class II patients. These results provide a

strong basis for targeting Celacade's novel anti-inflammatory

mechanism in this large and well-defined patient population."

As previously announced, a conference call will be conducted on October 9, 2007, at 4:30 p.m. Eastern time. The conference call may be accessed by calling 416-641-6124 or 1-866-300-4047 ten minutes prior to the call. An audio web cast of the event will also be available at http://www.vasogen.com. A re-broadcast of the conference call may be accessed by calling 416-695-5800 or 1-800-408-3053, PIN code 3238234 followed by the number sign, and will also be available at http://www.vasogen.com.

About Vasogen:

Vasogen is a biotechnology company
'/>"/>

SOURCE Vasogen Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... FLORHAM PARK, N.J. , March 30, 2015 ... antagonist (PAMORA) under development by Shionogi & Co., ... a phase III study (COMPOSE I) for the ... with chronic non-cancer pain receiving opioid therapy. Study ... once daily) statistically significantly improved the frequency of ...
(Date:3/29/2015)... 29, 2015  Caris Life Sciences® today announced ... Molecular Intelligence®, the company,s panomic, comprehensive tumor profiling ... several rare and difficult to treat gynecological cancers ... potential to improve patient outcomes. These studies were ... Society of Gynecologic Oncology (SGO) 2015 Annual Meeting ...
(Date:3/29/2015)... (PRWEB) March 29, 2015 As a ... often required by our pharmaceutical manufacturing clients, Whitehouse Laboratories ... sponsorship of the Berkenstock Race Team for the 2015 ... not only speed, but a strong sense of precision ... that lead to success in the quality control testing ...
(Date:3/27/2015)... , 27. März 2015  Peter Walter ... Biomedical Science für seine bahnbrechende Arbeit ausgewählt, ... Zellkompartimenten transportiert werden, sowie für die Entschlüsselung ... Reaktion auf Stress nutzen, der mit der ... ist Professor für Biochemie an der University ...
Breaking Biology Technology:Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4
... -Company,s New Name is PROLOR Biotech, Inc.- , , ... -Shareholders Approve Re-Election of Board of Directors and Other Proposals- ... (OTC Bulletin Board: MODG) today announced that shareholders approved a ... at its Annual Meeting of Shareholders held on May 21, ...
... sale in the United Statesfor treatment of pain and fever ... Cumberland Pharmaceuticals ( www.cumberlandpharma.com ) today announced ... Caldolor(TM) , an intravenous formulation of ibuprofen, through a priority ... for sale in the United States for the treatment of ...
... SEATTLE, June 11 ... results of a,large-scale Phase III study of Circadin(R) ... efficacy and safety in elderly patients.,The results were ... SLEEP,2009, the 23rd Annual Meeting of the Associated ...
Cached Biology Technology:Modigene Shareholders Approve Company Name Change and Other Proposals at Annual Meeting 2Cumberland Pharmaceuticals Announces FDA Approval of Caldolor(TM) 2Cumberland Pharmaceuticals Announces FDA Approval of Caldolor(TM) 3Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly Patients 2
(Date:3/10/2015)... PROVO, Utah , March 10, 2015   ... genome interpretation, has been selected by next-generation sequencing company ... provider of whole exome and targeted gene panel interpretation. ... sequencing provider, has adopted the most current technologies to ... of genetic research. The company offers two types of ...
(Date:3/5/2015)... 5, 2015 In Brazil , ... already using these solutions and 42 percent planning to invest ... approximately 25 percent of the companies will be investing in ... majority of companies in the region are currently opting for ... model will command significant attention in the coming years. This ...
(Date:3/3/2015)... FOREST, Calif. , March 3, 2015 ... the leading provider of advanced cryogenic logistics ... markets including immunotherapies, stem cells, cell lines, ... and reproductive medicine, today announced the expansion ... Cancer Research Centers, ("Fred Hutch") Clinical ...
Breaking Biology News(10 mins):PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... in the United States National Museum of Natural History ... Insects, researchers have found 16 new species of wasps ... species. The new species are described and illustrated ... a Key of the Charipinae (Hymenoptera: Cynipoidea: Figitidae) From ...
... recommendations is weak among people suffering from metabolic syndrome ... the Nordic SYSDIET study led by the University of ... high in salt and saturated fat, and too low ... have a sufficient intake of vitamin D. Metabolic syndrome ...
... can cause functional inhibition of remote regions such ... diaschisis. This phenomenon is often analyzed using positron ... these methods are expensive and radioactive. Dr. Yunjun ... Wenzhou Medical University in China quantified the changes ...
Cached Biology News:Nordic study: Few persons with metabolic syndrome adhere to nutrition recommendations 2